11 completed. 11 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 11 |
| Phase 1 | 2 | Completed 2 |
Follow Ipratropium: new trials by email Literature Review of Ipratropium trials Research Report on Ipratropium
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Combination of an Inhaled Budesonide and Ipratropium in Patients at Risk of Developing ARDS combined standard aerosolized doses of budesonide (0.5 mg/2 mL) every 12 hours and ipratropium bromide (500/2 mL) every eight hours for up to five days, Placebo - ARDS, Prevention and Control | Phase 1 / Phase 2 | Completed | Damanhour University | 119 | 2024-05-01 | 2025-02-06 |
| Treating Respiratory Emergencies in Children Study Ipratropium Bromide - Asthma in Children | Phase 2 | Completed | Oregon Health and Science University | 44 | 2024-01-19 | 2026-04-24 |
| Revefenacin in Acute Respiratory Insufficiency in COPD Revefenacin Inhalation Solution [Yupelri], Ipratropium Bromide - COPD, Acute Respiratory Failure | Phase 2 | Completed | University of California, Los Angeles | 21 | 2020-11-01 | 2026-10-14 |
| Atrovent in Exercise Induced Laryngeal Obstruction (EILO) Ipratropium bromide spray - Exercise Induced Laryngeal Obstruction (EILO) | Phase 1 / Phase 2 | Completed | Haukeland University Hospital | 20 | 2016-06-22 | 2024-08-19 |
| The Effects of RPL554 on Top of Standard COPD Reliever Medications Salbutamol, Ipratropium, RPL554 - Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 36 | 2015-10-01 | 2016-09-09 |
| Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study EP-101 via nebulizer (eFlow®) 25 ug, EP-101 via nebulizer (eFlow®) 50 ug, EP-101 via nebulizer (eFlow®) 100 ug - Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | Sunovion Respiratory Development Inc. | 140 | 2011-08-01 | 2018-05-09 |
| Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Placebo, TD-4208 700 μg, TD-4208 350 μg - Chronic Obstructive Pulmonary Disease, COPD | Phase 2 | Completed | Mylan Inc. | 32 | 2011-05-01 | 2022-02-24 |
| PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) PT001 MDI, Ipratropium Bromide HFA Inhalation Aerosol, Placebo MDI - Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | Pearl Therapeutics, Inc. | 103 | 2011-05-01 | 2018-06-20 |
| Aridol Challenge as a Tool to Predict Treatment Response to Inhaled Corticosteroids in COPD Dry powder mannitol, Budesonide 400mcg administered via turbuhaler, Ipratropium bromide 80mcg - Lung Diseases, Obstructive | Phase 2 | Completed | Syntara | 140 | 2005-07-01 | 2016-04-20 |
| Ipratropium Spray for Drooling Saliva in Parkinson's Disease ipratropium bromide (drug) - Parkinson's Disease | Phase 2 | Completed | University Health Network, Toronto | 20 | 2004-11-01 | 2018-02-20 |
| Study to Assess the Safety of Ipratropium Bromide, in Patients With Chronic Obstructive Pulmonary Disease (COPD) Ipratropium Bromide low dose, Placebo, Ipratropium Bromide high dose - Pulmonary Disease, Chronic Obstructive | Phase 2 | Completed | Boehringer Ingelheim | 57 | 1998-07-01 | 2014-09-12 |
Pulmonary Disease, Chronic Obstructive (6) · Lung Diseases, Obstructive (1) · Parkinson Disease (1) · Sialorrhea (1)
Boehringer Ingelheim (1) · Damanhour University (1) · Haukeland University Hospital (1) · Mylan Inc. (1) · Oregon Health and Science University (1) · Pearl Therapeutics, Inc. (1) · Sunovion Respiratory Development Inc. (1) · Syntara (1) · University Health Network, Toronto (1) · University of California, Los Angeles (1) · Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA (1)
United States (4) · United Kingdom (2) · Australia (1) · Canada (1) · Egypt (1) · New Zealand (1) · Norway (1)
Ahmet Tutuncu, M.D., Ph.D. (1) · Alan James, MBBS (1) · Alvin Ing, MBBS (1) · Chris Steinfort, MBBS (1) · Colin Reisner, M.D. (1) · Dave Singh (1) · David Langton, MBBS (1) · Donald Tashkin, MD (1) · Fred de Looze, MBBS (1) · Igor Z Barjaktarevic, MD, PhD (1) · Martin Coffey, MBBS (1) · Matthew L Hansen, MD, MCR (1) · Maureen McKeirnan, MBBS (1)
PMID 29506504, PMID 30166326, PMID 33124005, PMID 36699648, PMID 41943480
2015 (1)